Bladder cancer
- 1 May 1999
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Oncology
- Vol. 11 (3) , 207-12
- https://doi.org/10.1097/00001622-199905000-00013
Abstract
Bladder tumor antigen, nuclear matrix protein 22, telomerase activity, fibrin degradation products assay, and a number of diagnostic tests on exfoliated urethelial cells are being tried to replace or decrease the frequency of cystoscopies. The results of these studies have shown that although some of these tests are promising, the standard of care for patients with hematuria or previously treated bladder carcinoma is still cystoscopy. New and non-invasive tests are on the horizon, however. It is essential to find accurate prognostic factors in patients with T1 disease which will predict the cases which will progress to muscle invasive disease. It has been clearly shown that the depth of invasion within the submucosa is closely related with survival. It has been established that continent diversions improve the quality of life in patients who have undergone cystectomy. Furthermore, this type of diversion was shown to improve survival. This fact can be attributed to early cystectomy which was prompted by the increased patient acceptance.Keywords
This publication has 20 references indexed in Scilit:
- Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancerUrology, 1998
- CAN URINE BOUND DIAGNOSTIC TESTS REPLACE CYSTOSCOPY IN THE MANAGEMENT OF BLADDER CANCER?Journal of Urology, 1998
- Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activityCancer, 1998
- EVALUATION OF NMP22 IN THE DETECTION OF TRANSITIONAL CELL CARCINOMA OF THE BLADDERJournal of Urology, 1998
- The Bard® BTA Test: Its Mode of Action, Sensitivity and Specificity, Compared to Cytology of Voided Urine, in the Diagnosis of Superficial Bladder CancerEuropean Urology, 1998
- T1 and T2 Bladder Cancer: Selecting Optimal TherapyEuropean Urology, 1998
- Clinical evaluation of the BTA trak assay and comparison to voided urine cytology and the bard BTA test in patients with recurrent bladder tumorsUrology, 1997
- THE BLADDER TUMOR ANTIGEN (BTA) TEST COMPARED TO VOIDED URINE CYTOLOGY IN THE DETECTION OF BLADDER NEOPLASMSJournal of Urology, 1997
- RAPID PROTECTION OF BLADDER CANCER: A COMPARATIVE STUDY OF POINT OF CARE TESTSJournal of Urology, 1997
- Use of a New Tumor Marker, Urinary NMP22, in the Detection of Occult or Rapidly Recurring Transitional Cell Carcinoma of the Urinary Tract Following Surgical TreatmentJournal of Urology, 1996